Flavin‐Containing Monooxygenase 3 Polymorphic Variants Significantly Affect Clearance of Tamoxifen and Clomiphene
- 30 June 2018
- journal article
- research article
- Published by Wiley in Basic & Clinical Pharmacology & Toxicology
- Vol. 123 (6) , 687-691
Abstract
Human flavin‐containing monooxygenase 3 (hFMO3) is a drug‐metabolising enzyme that oxygenates many drugs and xenobiotics in the liver. This enzyme is also known to exhibit single nucleotide polymorphisms (SNPs) that can alter the rates of monooxygenation of therapeutic agents. The purpose of this study was to investigate the effect of the three common polymorphic variants ofhFMO3 (V257M, E158K and E308G) on the metabolism and clearance of three structurally similar compounds: tamoxifen (breast cancer medication), clomiphene (infertility medication) andGSK5182 (antidiabetic lead molecule). ForGSK5182, none of the three variants showed any significant differences in its metabolism when compared to the wild‐type enzyme. In the case of clomiphene, two of the variants, V257M and E308G, exhibited a significant increase in all the kinetic parameters measured with nearly two times faster clearance. Finally, for tamoxifen, a mixed behaviour was observed; E158K variant showed a significantly higher clearance compared to the wild type, whereas V257M mutation had the opposite effect. Overall, the data obtained demonstrate that there is no direct correlation between theSNPs and the metabolism of these threehFMO3 substrates. The metabolic capacity is both variant‐dependent and substrate‐dependent and therefore when testing new drugs or administering already approved therapies, these differences should be taken into consideration.Keywords
This publication has 23 references indexed in Scilit:
- Bioelectrochemical profiling of two common polymorphic variants of human FMO3 in presence of graphene oxideElectrochimica Acta, 2017
- Drug metabolism by flavin-containing monooxygenases of human and mouseExpert Opinion on Drug Metabolism & Toxicology, 2016
- Effect of Human Flavin-Containing Monooxygenase 3 Polymorphism on the Metabolism of Aurora Kinase InhibitorsInternational Journal of Molecular Sciences, 2013
- Flavin-containing monooxygenases: mutations, disease and drug responseTrends in Pharmacological Sciences, 2008
- Effect of Genetic Variants of the Human Flavin-Containing Monooxygenase 3 on N- and S-Oxygenation ActivitiesDrug Metabolism and Disposition, 2007
- Identification and Functional Analysis of Common Human Flavin-Containing Monooxygenase 3 Genetic VariantsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Mammalian flavin-containing monooxygenases: structure/function, genetic polymorphisms and role in drug metabolismPharmacology & Therapeutics, 2005
- The implications of polymorphisms in mammalian flavin-containing monooxygenases in drug discovery and developmentDrug Discovery Today, 2004
- TWO NEW POLYMORPHISMS OF THE FMO3 GENE IN CAUCASIAN AND AFRICAN-AMERICAN POPULATIONS: COMPARATIVE GENETIC AND FUNCTIONAL STUDIESDrug Metabolism and Disposition, 2003
- Flavin-containing monooxygenase isoform specificity for the N-oxidation of tamoxifen determined by product measurement and NADPH oxidationJournal of Biochemical and Molecular Toxicology, 1999